Bapineuzumab

A4DAB033 | Neurological disorders | Phase-II

Target APP

Isotype / Subclass G1 / IgG1

Company

JANSSEN Alzheimer Immunotherapy Pfizer Wyeth Elan Corporation

Clinical Status Phase-II

Format Whole mAb

Synonyms

AAB-001 AAB001

pH Formulation —

IMGT PubChem (135311552) PubChem (160703828) PubChem (178103512) PubChem (347911230) PubChem (472399323) PubChem (472435518) PubChem (472440364) PubChem (481155507) PubChem (505556656) PubChem (519878786) Thera-SAbDab YAbS

Avg A4D Score

-0.7132

Score Range

-0.73 to -0.7

Structures

2

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB033_4hix_H_L	4hix	98%	-0.7262	6.5	9.0	-0.5081	-0.755
A4DAB033_4ojf_H_L	4ojf	98%	-0.7003	6.5	9.0	-0.4708	-0.7306

Bapineuzumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2